“Even though it uses a production technology analogous to that of Vaxzevria (AstraZeneca’s immunizer), Covishield as such is not currently approved by EU regulations,” the European Medicines Agency (EMA) said in a statement to AFP.
“This is because vaccines are biological products. Even small differences in manufacturing conditions can lead to differences in the final product, and EU legislation requires that manufacturing sites and production processes be evaluated and approved as part of the production process. authorization”.
To date, there are four vaccines licensed in the EU: Pfizer/BioNTech, Moderna, AstraZeneca and Johnson & Johnson. Four others are “in the process of review” for possible approval: Russian Sputnik, Chinese Sinovac, German CureVac and American Novavax.
The World Health Organization (WHO) gave its approval to Covishield and lamented that some countries reject the product.
The African Union criticized that the lack of authorization in the EU of the low-cost vaccine made in India could cause disruption in Africa, where it is widely distributed.
“It’s a big shame because AstraZeneca-Covishield is exactly the same vaccine as AstraZeneca-Vaxzevria, which is accepted for vaccination,” said Richard Mihigo of the WHO regional office for Africa on Tuesday.
“The only difference is that AstraZeneca-Covishield is manufactured and distributed in other parts of the world outside of Europe,” he added.